Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs IQIYI Inc - ADR (IQ) Price & Performance

Citius Pharmaceuticals IncTrade
IQIYI Inc - ADRTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while IQIYI Inc - ADR trades at $1.35 (market cap $1.30B). The key difference: IQIYI Inc - ADR is far larger — about 65× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRIQ
Market Cap
$20.01M$1.30B
Sector
HealthMedia
52-Week High
$1.82$2.79
52-Week Low
$0.48$0.96
Enterprise Value
$16.23M$2.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

No Aura AI signal available yet.

IQIYI Inc - ADR

iQIYI (IQ) trades at $1.36, up 2.26% today, with a bullish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion. Valuation ratios show a high P/E of 144.05 but attractive P/S of 0.33 and P/B of 0.67. Recent news highlights AI platform growth and leadership changes, with Q2 2026 earnings due August 18, 2026.

The outlook is mixed: analyst consensus is 50% buy, but profitability challenges and revenue declines pose risks. Upside potential exists from AI initiatives and cost controls, yet competitive pressures and regulatory uncertainty in China remain headwinds. The stock offers speculative value for turnaround bets, balanced by fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About IQIYI Inc - ADR

iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.

Read more on IQ